Login
$SEPN
$41.67 -$0.93 (2.18%) Live

$SEPN SEC Filings

Filed On Filing
16 Nov 2026 Form 4: Finer Jeffrey, Director

Received 18,500 shares by exercise or conversion ($51.1K) · Sold 18,500 shares ($807K)

16 Nov 2026 144
13 Nov 2026 Form 4: Ezekowitz Alan, Director

Sold 81,820 shares ($3.93M)

12 Nov 2026 144
12 Nov 2026 144
12 Nov 2026 144
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027

04 Nov 2026 8-K: Regulation FD Disclosure

Exhibit 99.2 Pioneering a New Era of GPCR Drug Discovery Corporate Presentation November 2026 Nasdaq: SEPN © 2026 SEPTERNA

19 Oct 2026 Form 4: Bhatt Elizabeth, President and COO

Received 4,000 shares by exercise or conversion ($27.2K) · Sold 4,000 shares ($150K)

01 Oct 2026 144
01 Oct 2026 144
10 Sep 2026 Form 4: Patni Rajiv, Chief Medical Officer

Granted 275,000 Stock Option (Right to Buy)

03 Sep 2026 Form 3: Patni Rajiv, Chief Medical Officer

No securities owned

03 Sep 2026 Form 4: Long Daniel D., SVP, Drug Discovery

Received 3,333 shares by exercise or conversion ($9.2K) · Sold 3,333 shares ($126K)

25 Aug 2026 8-K: Regulation FD Disclosure; Other Events

SOUTH SAN FRANCISCO, Calif. – August 25, 2026 – Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patn...

14 Aug 2026 Form 4: Third Rock Ventures V, L.p., 10% owner and 5 others

Acquired 147,200 shares (Open Market Sale) ($7.4M)

14 Aug 2026 SCHEDULE 13D/A
14 Aug 2026 Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others

Sold 1,493,000 shares ($63.5M)

14 Aug 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support